



## Table of Contents

Figure S1 .....	3
Figure S2 .....	4

## SUPPLEMENTARY FIGURES



**Figure S1. Cilostazol does not improve lipid and glucose profile in NASH mice.** (A) Gross phenotype of liver. (B) Liver weight. (C) Liver weight / body weight. (D) steatosis score. (E) Triglyceride. (F) Non-esterified fatty acid. (G) Total cholesterol. (H) Fasting blood sugar. (I) Glucose tolerance test. (J) Insulin tolerance test.



**Figure S2. The effect of cilostazol on the progression of NASH to HCC in NASH mice.** We performed the histological evaluation of liver tissue to investigate the role of cilostazol in NASH-induced HCC. The H&E slides of 14-week-old STAM<sup>TM</sup> mice showed a well-circumscribed mass composed of cells with nuclear atypia forming the trabecular pattern, histologically consistent with well-differentiated HCC. In contrast, the sections of cilostazol-administered mice exhibited no definite mass-like lesion.